Leap Therapeutics (NASDAQ:LPTX) Price Target Lowered to $4.00 at Robert W. Baird

Leap Therapeutics (NASDAQ:LPTXGet Rating) had its price objective cut by Robert W. Baird to $4.00 in a report released on Monday, Stock Target Advisor reports.

Separately, Raymond James reduced their price objective on Leap Therapeutics from $3.50 to $2.50 and set an outperform rating on the stock in a research report on Friday, November 11th.

Leap Therapeutics Stock Down 2.6 %

Shares of LPTX stock opened at $0.59 on Monday. The firm has a market capitalization of $58.44 million, a P/E ratio of -1.26 and a beta of 0.61. Leap Therapeutics has a twelve month low of $0.55 and a twelve month high of $3.45. The stock’s fifty day simple moving average is $0.86 and its 200 day simple moving average is $1.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LPTX. M28 Capital Management LP lifted its holdings in Leap Therapeutics by 166.4% during the 1st quarter. M28 Capital Management LP now owns 2,664,400 shares of the company’s stock worth $4,663,000 after buying an additional 1,664,400 shares during the period. 683 Capital Management LLC lifted its holdings in Leap Therapeutics by 57.3% during the 3rd quarter. 683 Capital Management LLC now owns 2,265,000 shares of the company’s stock worth $1,993,000 after buying an additional 825,179 shares during the period. Tri Locum Partners LP acquired a new position in Leap Therapeutics during the 3rd quarter worth about $626,000. Renaissance Technologies LLC acquired a new position in Leap Therapeutics during the 2nd quarter worth about $714,000. Finally, Knott David M Jr lifted its stake in shares of Leap Therapeutics by 1,529.3% in the 2nd quarter. Knott David M Jr now owns 408,953 shares of the company’s stock valued at $470,000 after purchasing an additional 383,853 shares during the period. 38.08% of the stock is owned by institutional investors and hedge funds.

About Leap Therapeutics

(Get Rating)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Read More

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.